Skip to main content
. 2020 May 19;11:740. doi: 10.3389/fphar.2020.00740

Table 2.

Oncological diseases and antineoplastic treatments.

cTnI <6 ng/L (n=387) cTnI 6–40 ng/L (n=63) cTnI > 40 ng/L (n=35) NT-proBNP > 125 pg/ml (n=159) Total cohort (n=485)
Oncological disease
 Breast cancer 104 (27) 8 (13) 6 (17) 35 (22) 118 (24)
 Malignant melanoma 116 (30) 11 (17) 3 (9) 22 (14) 130 (27)
 Multiple myeloma 23 (6) 6 (10) 3 (9) 13 (8) 32 (7)
 Lymphoma 28 (7) 2 (3) 6 (17) 14 (9) 36 (7)
 Leukemia 39 (10) 8 (13) 9 (26) 24 (15) 56 (12)
 Small-cell lung cancer 13 (3) 1 (2) 1 (3) 5 (3) 15 (3)
 Merkel cell carcinoma 8 (2) 0 (0) 4 (11) 6 (4) 12 (2)
 Gastrointestinal cancer 11 (3) 3 (5) 0 (0) 12 (8) 14 (3)
Antineoplastic treatment
Conventional chemotherapy
(total)
243 (63) 38 (60) 29 (83) 117 (74) 310 (64)
 Anthracycline 87 (22) 13 (21) 14 (40) 51 (32) 114 (24)
 Alkylation 148 (38) 27 (43) 20 (57) 59 (37) 195 (40)
 Taxane 61 (16) 5 (8) 13 (37) 11 (7) 79 (16)
 Pyrimidine antagonist 11 (3) 4 (6) 3 (9) 11 (7) 18 (4)
 Purine antagonist 10 (3) 4 (6) 1 (3) 5 (3) 15 (3)
 Proteasome inhibitor 4 (1) 0 (0) 3 (9) 4 (3) 7 (1)
Tyrosine kinase inhibitor 52 (13) 9 (14) 1 (3) 17 (11) 62 (13)
HER2/neu inhibitor 24 (6) 3 (5) 4 (11) 15 (9) 31 (6)
PD1 inhibitor 90 (23) 9 (14) 4 (11) 25 (16) 103 (21)
BRAF inhibitor 17 (4) 3 (5) 1 (3) 4 (3) 21 (4)
MEK inhibitor 21 (5) 2 (3) 2(6) 5 (3) 25 (5)
Radiation 89 (23) 13 (21) 5 (14) 39 (25) 107 (22)
Surgery 149 (39) 22 (35) 10 (29) 58 (36) 181 (37)

Values are presented as the number of patients (percent)

BRAF, B-rapidly growing fibrosarcoma; cTnI, cardiac troponin I; HER2, human epidermal growth factor receptor 2; MEK, mitogen-activated protein kinase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PD1, programmed cell death protein 1.